PFE · Earnings call · 2026Q3T · Full report

Product / Drug Pipeline Progress

PFIZER INC · 2026-11-03 · Importance 30 · Surprise 24

Pfizer is developing tilrekimig, an in-house trispecific antibody targeting IL-4, IL-13, and TSLP, for atopic dermatitis and other type 2 inflammatory diseases. Phase 2 results showed a placebo-adjusted EASI-75 response of about 50% at the top monthly doses, and Pfizer said its Phase 3 program includes a head-to-head study against dupilumab. The company also has late-stage studies underway in severe asthma and COPD, with management citing potential across nine diseases with validated pathways.

Key facts

• Pfizer expects an update on its oral STAT6 program later in 2026 after adding DDI studies.
• Pfizer is starting additional berobenatide studies for knee osteoarthritis and obstructive sleep apnea, with or without CPAP.
• Pfizer expects to announce additional berobenatide Phase 3 studies in the coming months and additional studies in 2027 involving inflammation and oncology.
• Pfizer plans to advance 10 active and planned Phase 3 trials in its obesity portfolio in 2026.
• One planned Phase 3 obesity trial will evaluate switching from approved weekly therapies to Pfizer's investigational monthly GLP-1 peptide berobenatide.
• Pfizer's MEVPRO-1 readout is expected in Q1 2027 based on the current event rate.
• Pfizer expects MEVPRO-2 to read out in Q4 2027.
• Pfizer has several Phase 3 trials ongoing and expects pipeline catalysts over the next 18 to 24 months.